Liao X, Xie M, Li S, Yu X
Perioper Med (Lond). 2023; 12(1):27.
PMID: 37337277
PMC: 10278340.
DOI: 10.1186/s13741-023-00317-z.
Li S, Song L, Ma Y, Lin X
BMC Anesthesiol. 2020; 20(1):97.
PMID: 32345223
PMC: 7187521.
DOI: 10.1186/s12871-020-01018-6.
Li S, Li H, Ni J, Ma Y
BMC Anesthesiol. 2019; 19(1):37.
PMID: 30885134
PMC: 6421662.
DOI: 10.1186/s12871-019-0708-8.
Salama A
J Anaesthesiol Clin Pharmacol. 2017; 33(1):76-80.
PMID: 28413276
PMC: 5374834.
DOI: 10.4103/0970-9185.202191.
Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M
Naunyn Schmiedebergs Arch Pharmacol. 2012; 386(1):71-8.
PMID: 23224420
DOI: 10.1007/s00210-012-0814-3.
Management of urinary incontinence.
DeMaagd G, Davenport T
P T. 2012; 37(6):345-361H.
PMID: 22876096
PMC: 3411204.
Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder.
Igawa Y, Aizawa N, Homma Y
Korean J Urol. 2011; 51(12):811-8.
PMID: 21221199
PMC: 3016425.
DOI: 10.4111/kju.2010.51.12.811.
Muscarinic receptor expression increases following exposure to intravesical pressures of < or =40 cm-H2O: a possible mechanism for pressure-induced cell proliferation.
Lee S, Misseri R, Akbal C, Jung C, Rink R, Kaefer M
World J Urol. 2008; 26(4):387-93.
PMID: 18563417
DOI: 10.1007/s00345-008-0268-x.
Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study.
Song C, Park J, Heo K, Lee K, Choo M
J Korean Med Sci. 2006; 21(6):1060-3.
PMID: 17179687
PMC: 2721929.
DOI: 10.3346/jkms.2006.21.6.1060.
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
Dmochowski R, Nitti V, Staskin D, Luber K, Appell R, Davila G
World J Urol. 2005; 23(4):263-70.
PMID: 16151816
DOI: 10.1007/s00345-005-0012-8.
Contemporary and emerging drug treatments for urinary incontinence in children.
Humphreys M, Reinberg Y
Paediatr Drugs. 2005; 7(3):151-62.
PMID: 15977961
DOI: 10.2165/00148581-200507030-00002.
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.
Dmochowski R
Drug Saf. 2005; 28(7):583-600.
PMID: 15963006
DOI: 10.2165/00002018-200528070-00003.
Confusion about measuring central nervous system effects.
Madersbacher H
Curr Urol Rep. 2004; 5(6):442-6.
PMID: 15541213
DOI: 10.1007/s11934-004-0068-9.
Trospium chloride in the management of overactive bladder.
Rovner E
Drugs. 2004; 64(21):2433-46.
PMID: 15482001
DOI: 10.2165/00003495-200464210-00005.
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
Kershen R, Hsieh M
Curr Urol Rep. 2004; 5(5):359-67.
PMID: 15461912
DOI: 10.1007/s11934-004-0083-x.
Trospium chloride: a quaternary amine with unique pharmacologic properties.
Pak R, Petrou S, Staskin D
Curr Urol Rep. 2003; 4(6):436-40.
PMID: 14622495
DOI: 10.1007/s11934-003-0023-1.
